Trevi Therapeutics, INC. (TRVI) — 10-Q Filings

All 10-Q filings from Trevi Therapeutics, INC.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (6)

Trevi Narrows Q3 Loss Amid Haduvio Development, Boosts Cash Reserves — Nov 13, 2025 Risk: high
Trevi Therapeutics, Inc. (TRVI) reported a net loss of $11.802 million for the three months ended September 30, 2025, an improvement from the $13.242 million ne
Trevi Therapeutics Widens Q2 Loss Amid Rising G&A Costs — Aug 7, 2025 Risk: high
Trevi Therapeutics, Inc. reported a net loss of $14.5 million for the three months ended June 30, 2025, compared to a net loss of $13.2 million for the same per
Trevi Therapeutics Files Q1 2025 10-Q — May 8, 2025 Risk: medium
Trevi Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial condition and results of operations. Key fin
Trevi Therapeutics Files Q3 2024 10-Q — Nov 6, 2024 Risk: medium
Trevi Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates. Key financia
Trevi Therapeutics Files Q2 2024 10-Q — Aug 8, 2024 Risk: medium
Trevi Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the second qua
Trevi Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — May 7, 2024 Risk: low
Trevi Therapeutics, Inc. (TRVI) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Trevi Therapeutics, Inc. filed a 10-Q report for the period ending

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX